The aim of this study is to assess the feasibility of CSC-targeted radioimmunotherapy of AML using an 211At-labeled anti-CXCR4 monoclonal antibody (211At-CXCR4 mAb). The gene discussed is CXCR4; the disease is acute myeloid leukemia.